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Darier’s disease (DD) is an autosomal dominant disor-
der caused by mutations in the ATP2A2 gene, encoding
sarco/endoplasmic reticulum Ca2-ATPase pump type
2b isoform (SERCA2b). Although >100 mutations in the
ATP2A2 gene were identified, no apparent relation be-
tween genotype/phenotype emerged. In this work, we
analyzed 12 DD-associated mutations from all of the re-
gions of SERCA2b to study the underlying pathologic
mechanism of DD and to elucidate the role of dimeriza-
tion in SERCA2b activity. Most mutations markedly af-
fected protein expression, partially because of en-
hanced proteasome-mediated degradation. All of the
mutants showed lower activity than the wild type pump.
Notably, several mutants that cause relatively severe
phenotype of DD inhibited the activity of the endoge-
nous and the co-expressed wild type SERCA2b. Impor-
tantly, these effects were not attributed to changes in
passive Ca2 leak, inositol 1,4,5-trisphosphate receptor
activity, or sensitivity to inositol 1,4,5-trisphosphate.
Rather, co-immunoprecipitation experiments showed
that SERCA2b monomers interact to influence the activ-
ity of each other. These findings reveal multiple molec-
ular mechanisms to account for the plethora of patho-
logic states observed in DD and provide the first
evidence for the importance of SERCA2b dimerization
in pump function in vivo.
Darier’s disease (DD,1 OMIM 124200), also known as kera-
tosis follicularis, is an autosomal dominant skin disorder char-
acterized by loss of adhesion between epidermal cells (acan-
tholysis) and abnormal keratinization (1). DD is also associated
with an increased prevalence of neuropsychiatric disorders in-
cluding bipolar disorders, schizophrenia, epilepsy, and mental
retardation (1). Recently, mutations in the ATP2A2 gene en-
coding the sarco/endoplasmic reticulum Ca2-ATPase pump
type 2b isoform (SERCA2b) have been identified as a cause of
DD (2). SERCA2b is a housekeeping protein, which is ex-
pressed ubiquitously and is responsible for Ca2 uptake into
the ER, including the agonist-mobilizable Ca2 pool (3, 4). By
determining ER Ca2 load, the SERCA2 pumps modulate sev-
eral parameters of the Ca2 signal. In resting cells, the
SERCA2 pump provides the bulk of the dynamic Ca2-buffer-
ing capacity to prevent large fluctuation in [Ca2]i (5). In stim-
ulated cells, SERCA2 controls the activity of the store-operated
Ca2 influx channel by preventing accumulation of Ca2 at the
mouth of the channels and their inhibition by [Ca2]i (6).
SERCA2b reloads the ER with Ca2 at the end of cell stimu-
lation (5) and between Ca2 spikes to determine the frequency
of Ca2 oscillations (7), and to control the diverse cellular
functions regulated by [Ca2]i and Ca
2 oscillations (8, 9).
Alteration in SERCA2 pump function by overexpression in
Chinese hamster ovary cells (10) or partial deletion in mice (7)
lead to adaptation of the Ca2 signaling machinery and Ca2-
regulated cell functions that translates to nearly normal phys-
iological response in the majority of organs and tissues. This
correlates with the lack of consistent defect in DD patient
platelet and heart function in which SERCA2 is the major
pump in the endo/sarcoplasmic reticulum (11). By contrast, all
of the DD-associated mutations cause moderate to severe skin
disorders and several mutations cause neuropsychiatric disor-
ders, suggesting particular susceptibility of these tissues to
reduction in SERCA2 activity. These intriguing observations
raise several questions, among them are noted as follows. (a)
How mutations associated with DD affect SERCA2 pump ac-
tivity? (b) Mutations in ATP2A2 that cause DD are found all
along the gene, and no phenotype-genotype could be deduced.
Can phenotype-genotype be found based on SERCA2 pump
activity? (c) Do selective mutants associated with DD affect
native SERCA pump activity to provide a mechanism for the
variable phenotypes? Partial answers to these questions can
further our understanding of SERCA2 pump function and how
mutations in the pump lead to DD.
In this work, we analyzed 12 SERCA2b mutants that cause
DD in an attempt to address these questions. Mutants were
selected from all of the regions of the protein. The clinical
description of the disease for the vast majority of the mutants
is incomplete and, for the most part, relies on a single patient
of a single affected family. This made it difficult to attempt
correlation between genotype and phenotype. Nevertheless,
relying on published information, we attempted to select one
group of mutants that was reported to affect only keratinocyte
function and one group that was reported to also cause neuro-
logical deficiencies. An analysis of protein expression revealed
a diverse effect of the DD-causing mutations on protein expres-
sion. Measurements of Ca2 uptake and co-immunoprecipita-
tion experiments showed interactions among SERCA2b mono-
mers and highlighted the role of the dimers in pump
regulation. Most notably, several mutants reduced the activity
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of the native and of co-expressed WT pumps. These findings
provide the first evidence to indicate physical and functional
interaction between SERCA2b monomers. Although no defini-
tive correlations between the mutations and DD phenotype
became apparent, probably because of poor clinical information
available for this disease, our findings do provide a molecular
mechanism to account for the disease pathogenesis and how
diverse phenotypes can be manifested.
EXPERIMENTAL PROCEDURES
Materials, Antibodies, and Solutions—Chelex, ATP, phosphocreati-
nine, creatinine phosphokinase, antimycin A, and oligomycin were pur-
chased from Sigma. Fluo-3 pentaammonium salt was from Molecular
Probes, Inc. (Eugene, OR). D-Myo-inositol 1,4,5-trisphosphate (IP3)
hexasodium salt was from Alexis Biochemicals (San Diego, CA). Strep-
tolysin O was from BD Diagnostic Systems (Sparks, MD). Lactacystin
and ionomycin were from Calbiochem. Fetal bovine serum and 0.05%
trypsin/EDTA were from ATLANTA Biologicals (Norcross, GA). Restric-
tion enzymes were obtained from New England Biolabs (Beverly, MA)
and Roche Applied Sciences.
Cell Culture and Transfection—HEK 293 cells were maintained in
Dulbecco’s modified Eagle’s medium containing 10 mM glucose supple-
mented with 10% fetal calf serum. The SERCA constructs were trans-
fected using LipofectAMINE reagent (Invitrogen). The cells were used
for immunoprecipitation or immunoblotting 48 h after transfection.
Site-directed Mutagenesis—The pcDNA3.1 plasmid containing hu-
man SERCA2b was a generous gift from Dr. Jonathan Lytton (Univer-
sity of Calgary, Calgary, Canada). Site-directed mutagenesis was per-
formed using the QuikChange site-directed mutagenesis kit from
Stratagene (La Jolla, CA) according to instructions provided by the
manufacturer. All of the mutations were verified by the sequencing of
four separate clones from each mutant. The mutants generated for this
work are listed in Table I.
Preparation of HA-tagged and Myc-tagged Human SERCA2b Con-
structs—HA- and Myc-tagged human SERCA2b constructs were gener-
ated by PCR amplification of human SERCA2b using the 5-oligonu-
cleotide primer 5-AC GTC AAT GGG TCG ACT ATT TAC G-3
containing the underlined SalI and 3-oligonucleotide primer 5-AGA
AGG CAC AGT CGA GGC TG-3 located after a NotI site. The amplified
DNA was gel-purified, digested with appropriate enzymes, and ligated
into the pCMV-HA or Myc vectors (Clontech Laboratories, Inc., Palo
Alto) that had been digested with SalI and NotI and gel-purified. The
constructs were verified by DNA sequencing.
Immunoprecipitation and Immunoblotting—Transfected HEK 293
cells were washed with phosphate-buffered saline and lysed with buffer
containing 135 mM NaCl, 0.1% Triton X-100, 20 mM Tris-HCl, pH 7.4,
and a proteinase inhibitor mixture (Roche Applied Sciences). Precleared
lysates (up to 500 g of protein) were mixed with 3 l of anti-HA
antibodies or anti-Myc antibodies and incubated for 2 h at 4 °C in lysis
buffer. Immune complexes were collected by overnight incubation with
50 l of protein G-agarose at 4 °C under gentle agitation. Immunopre-
cipitated proteins were washed four times with lysis buffer prior to
electrophoresis. The immunoprecipitates or lysates were suspended in
SDS sample buffer and separated by SDS-polyacrylamide gel electro-
phoresis. After transfer to nitrocellulose membranes, the proteins were
detected with the appropriate primary and secondary antibodies.
Measurement of Ca2 Uptake and Release in Permeabilized Cells—
HEK 293 cells were released, washed, and re-suspended in serum-free
Dulbecco’s modified Eagle’s medium containing 10 mM glucose. The
cells then were counted, and 3  106 cells were washed twice with a
high potassium solution (130 mM KCl and 10 mM HEPES, pH 7.4, with
NaOH). The cells were suspended in 50 l of Chelex-treated high
potassium solution and added to 0.45 ml of SLO-permeabilization me-
dium. The SLO-permeabilization medium was composed of resin-
treated 130 mM KCl and 10 mM HEPES solution supplemented with 3
mM ATP, 5 mM MgCl2, 10 mM phosphocreatinine, 30 units/ml creatinine
phosphokinase, 5 M antimycin A, 5 M oligomycin, 2 M Fluo-3, and
4.5 mg/ml SLO. The recording of Fluo-3 fluorescence was initiated upon
the addition of cells to a warm (37 °C) permeabilization medium and
was recorded at excitation and emission wavelengths of 488 and 530
nm, respectively. The cells were allowed to take up and reduce [Ca2] of
the permeabilization medium to 50–100 nM before the addition of IP3 or
BHQ. The Fluo-3 fluorescence signals were calibrated by the addition of
1 mM CaCl2 to the medium (Fmax), which was followed by the addition
of 5 mM EGTA and 30 mM NaOH to obtain Fmin. [Ca
2] was calculated
using a Kd of 370 nM at 37 °C.
RESULTS
Protein Levels of SERCA2b Mutants—Because haploinsuffi-
ciency cannot explain the variable phenotype of DD patients
(12), our initial hypothesis was that the severity of the disease
may correlate with protein expression levels. This hypothesis
was refuted by the finding that most DD mutants examined
affected SERCA2b expression and/or stability (Fig. 1A). With
the exception of two mutants (C344Y and V843F), all of the
mutants markedly reduced protein expression. The possibility
of variable SERCA2b expression because of variable transfec-
tion efficiency was excluded by the analysis of co-transfected
green fluorescent protein (Fig. 1B).
Effect of the N-terminal mutants is consistent with previous
work with SERCA1. Deletion of the N-terminal domain of
SERCA1 reduced protein expression (13). Accordingly, muta-
tion of SERCA2b Asn-39 to Asp or Thr reduced protein expres-
sion, suggesting that the integrity of the N terminus is impor-
tant for pump expression. Interestingly, all of the truncation
mutants including E917X markedly reduced protein expres-
sion, suggesting increased degradation of these pump products
(see below). No concrete conclusion emerged from the other
mutations. Thus, a mutation in the P domain (phosphorylation
domain), C334Y, had minimal effect on protein expression,
whereas another mutation, F487S, markedly reduced protein
expression. Similarly, G769R in TM5 reduced protein expres-
sion, whereas V843F in the TM8-TM9 loop had minimal effect.
Hence, the overall significance of the protein expression find-
ings to DD is that the mutations can affect pump activity by
multiple mechanisms. Some mutants affect pump activity be-
cause of reduced protein expression, whereas others such as
C344Y and V843F must act by a different mechanism. The
results in Fig. 1 together with the phenotypic information
listed in Table I indicate a lack of correlation between protein
expression and disease phenotype.
Proteasome-mediated Degradation of Mutant SERCA2b Pro-
tein—Previous work showed that lactacystin, a specific protea-
some inhibitor, enhanced degradation of WT SERCA1 and pre-
vented the small degradation of Ala3-SERCA1 but had no
effect on several other deletion or mutations between Glu2-
Ala14-SERCA1 (14). Therefore, we tested the effects of lacta-
cystin on SERCA2b protein levels. Several of the mutants that
showed low protein expression exhibited enhanced protein deg-
radation. However, as with protein expression, protein degra-
dation followed a complex pattern with respect to the effect of
individual mutants (Fig. 2). First, we confirmed the finding
FIG. 1. Effect of mutations associated with DD on SERCA2b
protein expression. HA-tagged WT or mutant SERCA and green
fluorescent protein (GFP) plasmids were transiently transfected in
HEK 293 cells. 5 g of protein/lane were separated on 8% HA (A) or 10%
GFP (B) SDS-polyacrylamide gels. Con, control.
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made with SERCA1 by observing slight increased degradation
of WT SERCA2b by lactacystin. Furthermore, lactacystin sim-
ilarly increased degradation of the C344Y and V843F mutants
that had minimal effect on protein expression. The group of
mutants most susceptible to degradation by the proteasome is
the nonsense and the premature translation termination
codon-inducing frameshift mutations (1625delAG). Lactacystin
increased the expression of these mutants between 5- and
20-fold (Fig. 2C). This finding indicates that the ER quality
control-mediated degradation machinery recognizes the trun-
cated SERCA2b mutants as misfolded proteins. Interestingly,
the inhibition of the proteasome did not have a similar effect on
all of the mutants. Furthermore, the mutants in the same
region had an opposite effect. Thus, lactacystin had no effect on
N39D but appeared to enhance expression of N39T, and it had
no effect on expression of L41 but enhanced the expression of
P42. Selective effect of lactacystin on the degradation of sev-
eral SERCA2b (this work) and SERCA1 mutants (14) suggest
that SERCA pumps are degraded by the proteasome and other
proteases. However, as with protein expression, no obvious
correlation between phenotype-genotype was apparent.
Ca2 Uptake Activity—The most interesting results were
obtained by measuring SERCA pump activity. Selective traces,
the experimental protocols, and the parameters tested are il-
lustrated in Fig. 3. A summary of pump activity of native cells,
cells transfected with the WT pump, and all of the mutants is
given in Fig. 4. Ca2 uptake into the ER was initiated by
adding cells to the SLO-containing permeabilization medium.
The uptake attained constant rate after completion of perme-
abilization, and Ca2 uptake rate was determined from the
nearly linear portion of the slopes as indicated by the dashed
lines in Fig. 3. At the end of the uptake period, the cells were
used to measure either IP3-mediated Ca
2 release (Fig. 3, A–C)
or the rate of ER-passive Ca2 leak by inhibition of SERCA2b
with BHQ (Fig. 3, D–F). Residual Ca2 in the stores was then
discharged by the addition of 2 M Ca2 ionophore ionomycin.
Expression of WT SERCA2b increased Ca2 uptake rate by
3-fold. Evaluation of Ca2 uptake by all of the mutants re-
vealed that only one mutant, V843F, which was expressed at
levels comparable to the WT pump, retained activity that was
approximately 50% that of the WT pump (Fig. 4). Six mutants
had no activity and did not affect Ca2 pumping by the native
SERCA pumps. The most interesting mutants were the 5 of the
12 tested (42%) (N39D, N39T, C344Y, F487S, and S920Y) that
reduced the activity of the native pumps.
Reduction of native Ca2-pumping activity raised the ques-
TABLE I
DD-associated mutations analyzed in this work
Mutation Nucleotidechange Consequence Exon Functional domain
Affected
patientsa Skin features
b Neuropsychiatric features
N39D 115A3G Missense 1 Upstream S1 1 family Moderate Hospitalization for
violent behavior
N39T 116A3C Missense 1 Upstream S1 None
L41 121delTTA In-frame
deletion
2 S1 Severe Suicide in family,
emotional problems
P42 124delCCG In-frame
deletion
2 S1 Severe Depression
C344 1031G3A Missense 8 M4/Phosphorylation 1 family Mild-moderate None
F487S 1460T3C Missense 12 Phosphorylation 1 family (4) Severe Schizophrenia, seizures,
depression
1625delAG (K542X) Frameshift
(PTC 
9aa)
13 ATP binding 1 family (2) Moderate (2) None
G769R 2305G3C Missense 15 M5
Q790X 2368C3T Nonsense 16 12 Multiple
neuropsychiatric
features
V843F 2527G3T Missense 17 M7 Epilepsy, major
depressive disorder
(single episode)
E917X 2749G3T Nonsense 19 M8–M9 loop None
S920Y 2759C3A Missense 19 M8–M9 loop 2 families
(5  3)
Mild (1), moderate (5),
severe (2)
Epilepsy(1), dysmorphic
facies, low-normal
I.Q.
a The number in parentheses indicates number of patients.
b Skin severity described was adapted after the categorization of Ringpfeil et al. (38).
FIG. 2. Proteasome-mediated deg-
radation of SERCA2b mutants. HA-
tagged WT or mutant SERCA plasmids
were transfected in two parallel sets of
HEK 293 cells. After 24 h, the cells were
incubated in media containing vehicle (A)
or 10 M lactacystin (B), and protein ex-
pression was determined 24 h later. C, a
summary of the results of three experi-
ments. Lac, lactacystin; Con, control.
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tion of relevance to DD where the WT and most mutants mRNA
are likely to be present at comparable levels. Therefore, to
simulate the DD situation, a 1:1 mixture of WT and the mutant
clones that reduced the activity of the native pump were trans-
fected and the resulting pumping activity measured. The re-
sults are summarized in Fig. 5. The expression of WT
SERCA2b again increased Ca2-pumping rate by 3-fold, and
this rate was taken as 100% control. Co-expression of WT and
the G769R mutant that had no effect on the native pump (Fig.
4) was used as an expression control, and as expected, it had no
effect on Ca2 pumping by the expressed WT SERCA2b. Fig. 5
shows that all of the mutants that reduced the activity of the
native pump similarly inhibited the activity of the expressed
WT SERCA2b, indicating that the inhibition is inheritant to
these mutants.
The poor clinical definition of DD phenotype makes it diffi-
cult to draw a precise correlation between the mutants that
inhibited WT SERCA2 activity and the disease phenotype.
However, the tendency is that mutants that cause a relatively
severe phenotype such as F487S and S920Y noticeably inhib-
ited endogenous and expressed WT SERCA2b activity. The
finding of reduced WT pump activity by the mutants provides
the first molecular mechanism that can account for the variable
DD phenotypes.
Passive Ca2 Leak and IP3 Sensitivity—The next question
we addressed is how the DD-associated mutations reduce WT
SERCA2b-pumping activity. One possibility is that the mutant
proteins increase passive Ca2 leak across the ER membrane,
resulting in an apparent reduced pumping rate. Increased pas-
sive leak was proposed to account for the inhibition of native
Ca2 pump activity by SERCA1 splice variants when expressed
in heterogeneous systems (15). In this work, we used a SERCA
pump inhibition protocol to estimate the Ca2 leak rate at the
end of the uptake period. Measurement of Ca2 leak with all of
the DD mutants used in this work (Fig. 3, D–F, BHQ addition)
showed that this mechanism cannot account for the reduced
FIG. 3. Ca2 uptake, IP3-mediated Ca
2 release and Ca2 leak in cells expressing WT and mutant SERCA2b. Approximately 48 h after
transfection, cells were released from culture plates and counted, and 3 106 cells were washed and added to permeabilization medium to measure
Ca2 uptake into the ER as described under “Experimental Procedures.” The rate of Ca2 pumping was determined from the slopes of reduction
in medium [Ca2]. Ca2 uptake was measured in control non-transfected HEK 293 cells (A and D) and cells transfected with F487S (B and E) and
WT SERCA2b (C and F). At the end of Ca2 uptake, IP3-mediated Ca
2 release was measured by the addition of increasing concentrations of IP3
at 0.15, 0.30, 0.45, and 2.95 M (A–C) and the rate of Ca2 leak was determined by inhibiting the pump with 100 M SERCA pump inhibitor BHQ
(D–F). Residual stored Ca2 was released by the addition of 2 M ionomycin (I) at the end of each experiment. All traces were calibrated as
described under “Experimental Procedures.”
FIG. 4. Ca2 transport by WT and
mutant SERCA2b pumps. The protocol
of Fig. 3 was used to evaluate pump ac-
tivity of all of the mutants. The number of
experiments is given in the columns. The
results are plotted as the mean  S.E. *
and #, statistically significant difference
of p  0.05 and p  0.01, respectively,
compared with control.
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SERCA pump activity, because none of the mutants increased
the passive Ca2 leak. Because SERCA pumps determine Ca2
content in the ER and the ER Ca2 load affect sensitivity to IP3
(5), another possibility is that the mutant pumps altered IP3-
mediated Ca2 release. The measurement of the extent of Ca2
release and its dependence on IP3 concentration showed that
none of the mutants had an apparent effect on IP3-mediated
Ca2 release (Fig. 3, A–C), confirming the results obtained in
the SERCA2b/ mice (7).
Interaction between SERCA2b Monomers—The simplest
mechanism by which the mutants can inhibit the activity of the
WT SERCA2b is reducing the expression of the pump; however,
this was found not to be the case (Fig. 6). The level of WT pump
protein was not affected by co-expression of any of the mutant
proteins. Equally, co-expression of the WT and mutant pumps
had no effect on expression of the mutant pumps.
A second alternative is that SERCA2b exists as a dimer and
the mutants, including those that are expressed at low levels,
interact with the WT pump to reduce its activity. A clue to this
possible mechanism is provided by earlier work suggesting that
SERCA pump monomers sense and are influenced by their
neighbors. Thus, the titration of Ca2-ATPase and Ca2 up-
take activities with fluorescein isothiocyanate (16), radiation
inactivation analysis of pump activity and integrity (17, 18),
freeze-fracture and deep-etching of sarcoplasmic reticular
membranes (19, 20), and analysis with photoaffinity spin-la-
beled derivative of ATP (21) all suggested that the functional
unit of the Ca2-ATPase is a dimer. Furthermore, an analysis
of a purified 48-kDa SERCA1 fusion protein by small angle
x-ray scattering suggested a requirement of the hinge domain
(amino acids 670–728) region for self-association of the large
hydrophilic domain into a dimer (22). Thus, it is possible that
the mutant pumps affect the WT pump by way of protein
interaction.
To test interaction between pump monomers, we attempted
to co-immunoprecipitate (co-IP) co-expressed HA- and Myc-
tagged SERCA2b. Initial attempts to do so failed. Fig. 7, A and
B, shows that when the cells were lysed with a medium con-
taining 1.0% Triton X-100 and 150 mM NaCl, it was possible to
immunoprecipitate each of the tagged monomers but not to
co-IP them. We then considered the possibility that interaction
among the SERCA2b monomers is subtle and could not with-
stand the harsh solubilization conditions. This was confirmed
by observing co-IP of the monomers when the cells were lysed
in a medium containing 0.1% Triton X-100 and 135 mM NaCl
(Fig. 7, C and D). Furthermore, co-IP of the SERCA2b mono-
mers could be observed when the cells were lysed with 1% of
the milder detergent Nonidet P-40 (data not shown). The find-
ings in Fig. 7 provide the first direct evidence that SERCA2b
monomers can interact with each other in vivo.
The functional consequence of dimerization of the SERCA2b
monomers can be deduced from examining the interaction of
the mutants with the WT pump. The results of such analysis
are displayed in Fig. 7, E and F. Several findings are noticea-
ble. First, most but not all SERCA2b mutants interact with the
WT pump, providing a plausible explanation for inhibition of
the native and expressed WT SERCA2b activity by the mu-
tants. Second, all of the extreme N-terminal mutants showed
reduced co-IP compared with their expression levels, implicat-
ing this region of the protein in dimerization. The same prob-
ably holds for the G769R mutation that showed good expres-
sion when expressed alone (Fig. 1 and 2) or together with the
WT pump (Fig. 6) but showed very poor co-IP (Fig. 7). Because
this mutation inserts an additional positive charge into TM5, it
may result in misfolding of the protein to prevent dimerization.
Third, all of the truncation mutants and the S920Y mutant
FIG. 6. DD mutants do not affect expression of WT SERCA2b.
Myc-tagged WT and HA-tagged WT or mutant SERCA2b plasmids were
co-transfected into HEK 293 cells. 5 g of protein were analyzed for
expression of both WT (A) and mutant pumps (B).
FIG. 5. Effect of selective mutants
on pump activity of co-transfected
WT SERCA2b. The protocol of Fig. 3 was
used to assay pump activity. WT
SERCA2b (A) alone or together with the
indicated mutants (B and C) were co-
transfected in HEK 293 cells. The effect of
all of the mutants that reduced the activ-
ity of the native pump (see Fig. 4) was
analyzed. The results are plotted as the
mean  S.E. * and #, denote statistically
significant difference of p  0.05 and p 
0.01, respectively, compared with control.
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showed preferential co-IP with the WT pump, more than ex-
pected from their expression. Because the truncation mutants
are the most susceptible to proteolysis (Fig. 3), the simplest
explanation for this finding is that dimerization protects these
mutants from proteolysis. However, the analysis of protein
expression levels in Fig. 6 does not support such an explana-
tion. Another possibility is that sequences C-terminal to posi-
tion Glu-917 (the shortest truncation tested) function to reduce
pump dimerization and their truncation resulted in enhanced
association of the truncated mutants with the WT pump. This
interpretation is supported by the finding that the only other
mutation to induce preferential binding is the S920Y and that
this portion of the protein between TM8 and the C terminus
appears to be the most rigid because it shows the least move-
ment upon transition from the E1 to the E2 conformation (23).
DISCUSSION
Ca2 pools have a key role in shaping the spatiotemporal
complexity of Ca2 signaling and in controlling cellular pro-
cesses of major physiological and pathological relevance (24).
SERCA pumps are key participants in the Ca2 signal as they
determine ER Ca2 content at rest and during stimulation (10).
In addition, several ER functions such as the activity of several
chaperones and that of the unfolded protein response are reg-
ulated by ER Ca2 content (25, 26). Thus, it is not surprising
that mutations in SERCA2 pump activity lead to DD. However,
DD is characterized by variable phenotypes from very mild
symptoms with dislodging of skin keratinocytes to severe mani-
festation with several neurological deficiencies.
The effect of DD-causing mutations on SERCA2b pump ac-
tivity is unknown, let alone the underlying mechanism for the
variable phenotype of the disease. In this work, we analyzed
several mutations that cause DD in an effort to partially ad-
dress these questions and to gain a further understanding of
SERCA2b pump function. All of the mutations analyzed with
the exception of one showed no Ca2-pumping activity, and the
V843F mutation reduced pump activity by 50%. Hence, it is
clear that the mutations that cause DD do so by reducing
SERCA2b activity. Multiple biochemical mechanisms appear
responsible for reduced pump activity. Thus, nonsense muta-
tions resulted in truncated pump proteins that were suscepti-
ble for degradation by the proteasome. Several missense mu-
tations caused a marked reduction in protein level that was
partially attributed to degradation by the proteasome, whereas
others had a minimal effect on pump expression. This variabil-
ity probably contributes to the variable clinical phenotype, but
it is not sufficient to account for all of the variability because 11
of the 12 mutants examined had no pumping activity.
The two most notable and related findings in this work are
the biochemical evidence for interaction between SERCA2b
monomers and the inhibition of the native and expressed WT
SERCA2b activity by five of the mutants. The crystal structure
of SERCA1 in the E1 (Ca2) (27) and E2 (2H) (23) conforma-
tions suggest that SERCA pumps can exist as monomers. Of
course, this does not exclude the possibility that in vivo the
monomers interact with each other or that the pump functions
as a dimer. Indeed, several lines of functional and biochemical
evidence (16–21) support this notion. Here we provided the
first direct evidence that SERCA2b exists as a dimer by show-
ing that HA-tagged and Myc-tagged pumps can be co-IPed
under mild extraction conditions. Importantly, all of the DD
mutants interacted with the WT pump.
The significance of interaction of the WT and mutant
SERCA2b monomers in vivo is that it provides a mechanism to
explain reduced Ca2 pumping below 50% that is expected
from the recessive nature of the disease. This provides a likely
mechanism to account for the variable clinical features of DD.
Hence, the essential role of SERCA2b in Ca2 signaling makes
it vital for life, and even a 50% reduction in pump activity is not
tolerated, leading to the detachment of skin keratinocytes.
Other cellular activities such as Ca2-dependent exocytosis (7)
and myocytes contractility (28) undergo adaptation to the mod-
ified Ca2 response. However, the interaction of WT and the
DD-causing mutants that leads to a further reduction of
SERCA2b pump activity is likely to affect additional cells and
organs such as the nervous system.
The clinical features of DD point to particular vulnerability
of keratinocytes and neuronal cells to mutations in SERCA2b
and Ca2 homeostasis in the ER. This suggests that a cellular
function common to the two cell types is particularly sensitive
to ER Ca2 content. Such a potential function can be cell-cell
and cell-matrix attachment that in keratinocytes are mediated
by cadherins, a family of calcium-dependent adherent proteins.
Cadherins also play a central role in the formation of neuronal
connections (29, 30) and may contribute to neurite outgrowth
FIG. 7. Interaction of SERCA2b monomers. HEK 293 cells transfected with empty vector (lane 1), HA-WT (lane 2), or HA-WT and Myc-WT
SERCA2b (lane 3) were used for the experiments in the blots (A–D). The cells were lysed 48 h after transfection with a buffer containing either
1% Triton X-100, 150 mM NaCl, 20 mM Tris-HCl, pH 7.4, and protease inhibitor mixture (A and B) or the same medium but with Tition X-100
reduced to 0.1% and NaCl reduced to 135 mM (C and D). The lysates were used to immunoprecipitate HA (middle three lanes in A and B) or Myc
(right three lanes in A and B and in C and D) and blot for HA (A and D) or Myc (B and C). Note that only when the cells were extracted with 0.1%
Triton X-100 and 135 mM NaCl, the SERCA2b monomers could be co-immunoprecipitated. E and F, cells were co-transfected with Myc-tagged WT
SERCA2b and the HA-tagged mutants and used for extraction with 0.1% Triton X-100. The extracts were used to immunoprecipitate Myc and were
probed for HA (E) and Myc (F). IP, immunoprecipitate; IB, immunoblot.
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and pathfinding and to synaptic specificity in the central nerv-
ous system (31). Aberrant function of cadherins can explain the
symptomatic skin disorders in DD and that the second most
prevalent disorder in DD is neurological deficiencies. If aber-
rant function of cadherins is the underlying cause of DD symp-
toms, our findings point to a central role of ER Ca2 in the
function of cadherins.
Most studies attribute Ca2 regulation of cadherins function
to extracellular Ca2 (32, 33). In fact, little is known regarding
the role of [Ca2]i in the regulation of cadherins function.
However, accumulating evidence points to such a role. Deple-
tion of ER Ca2 with thapsigargin and cyclopiazonic acid pre-
vented accumulation of cadherins at cell-cell junctions (34) and
increased endothelial permeability by increasing discontinui-
ties in cadherins junctions (35). Conversely, increased ER Ca2
load by overexpression of calreticulin, a Ca2 storage protein
and chaperone in the ER, enhances assembly of cadherins
junctions in cell-cell contacts (36). Significantly, dissociation of
cadherins was observed in the skin of patients with DD (37).
Together, these findings point to the importance of ER Ca2 in
cadherins function and their possible aberrant function in DD.
In summary, this work demonstrates multiple effects of mu-
tations in SERCA2b pump associated with DD. The mutations
affect protein expression, degradation, and activity. The most
significant finding is that several DD-associated mutants in-
hibit the activity of the native and the expressed WT pumps.
The inhibition was not the result of altered protein expression
nor increased passive leak but rather the inhibition of pumping
activity by protein-protein interaction. These findings provide
a plausible molecular mechanism for diverse phenotypes of DD
and a framework to further understand the role of SERCA2b in
specific cell functions.
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